RBC Capital analyst Shagun Singh raised the firm’s price target on Boston Scientific to $56 from $53 and keeps an Outperform rating on the shares. The company reported a "solid" Q1 earnings beat with double-digit gains across all divisions, the analyst tells investors in a research note. RBC adds that it expects Boston Scientific’s underlying business momentum to persist in 2023 and for new products to aid further growth into 2024.
Published first on TheFly
See the top stocks recommended by analysts >>
Read More on BSX:
- Boston Scientific commentary lowers odds of ShockWave deal, says Evercore
- Boston Scientific price target raised to $58 from $53 at Canaccord
- Boston Scientific price target raised to $56 from $53 at Barclays
- Boston Scientific Gains on Q1 Beat
- Boston Scientific raises FY23 adjusted EPS view to $1.90-$1.96 from $1.86-$1.93
